Send us Feedback

Titan Pharmaceuticals (TTNP)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
FDA Rejection of Titan's Probuphine Looks Like a Mugging
TheStreet.com  May 1  Comment 
SOUTH SAN FRANCISCO, Calif. (TheStreet) -- The U.S. Food and Drug Administration came down hard on Titan Pharmaceuticals , rejecting its Probuphine implantable therapy for opioid dependence and requesting a lot of new clinical data and other...
Titan Plunges After FDA Rejects Drug-Addiction Treatment
Bloomberg  May 1  Comment 
UPDATED: FDA steamrolls over panel vote, spurns Titan's addiction drug Probuphine
FierceBiotech  May 1  Comment 
Titan claims victory for anti-addiction drug after mixed FDA panel votes
FierceBiotech  Mar 22  Comment 
Titan Pharmaceuticals ($TTNP) emerged victorious from an FDA advisory committee meeting where the majority of non-agency experts backed approval of its drug against opioid addiction. While the agency hasn't made up its mind on the therapy,...
Titan Pharma: FDA Panel Live Blog
TheStreet.com  Mar 21  Comment 
Titan Pharma FDA Panel Live Blog BETHESDA, Md. (TheStreet) -- An FDA advisory panel will spend Thursday reviewing a long-acting treatment for opioid addiction from Titan Pharmaceuticals . The panel is expected to be contentious because...
Titan Pharma: Run-Up Trade Into March FDA Panel
TheStreet.com  Jan 31  Comment 
NEW YORK (TheStreet) -- Titan Pharmaceuticals is developing Probuphine, a proprietary, long-acting form of the opioid dependence drug buprenorphine. Probuphine is implanted just under the skin of the upper arm and provides continuous delivery of...
TehrikeTaliban-Pakistan-pledges-to-fight-in-Kashmir-implement-sharia-in-India
Financial Express  Jan 8  Comment 
TTP leader has pledged to send fighters in Kashmir for implementation of Sharia rule in India.
UPDATE: Bank of America Merrill Lynch Initiates Coverage on Tortoise Pipeline & Energy Fund with Neutral Rating
Benzinga  Oct 22  Comment 
In a report published Monday, Bank of America Merrill Lynch initiated coverage on Tortoise Pipeline & Energy Fund (NYSE: TTP) with a Neutral rating. BofA Merrill Lynch noted, “We are initiating coverage of Tortoise Pipeline and Energy Fund...
Cerus Enters Partnership With American Red Cross and Blood Systems
Benzinga  Sep 11  Comment 
Cerus Corporation (NASDAQ: CERS) announced today that it has entered into independent partnership agreements with both the American Red Cross and Blood Systems Incorporated (BSI) to commercialize INTERCEPT plasma for use in the orphan indication...
Imran Khan Vows To Protest in Waziristan, TTP Backs Off The Threat
Value Investing  Aug 10  Comment 
Cricketer-turned politician, Imran Khan is determined to conduct the public rally to protest against the drone attacks in the North Waziristan region. The chief of Pakistan Tehrik-e-Insaf (PTI) declared that his plan of the Waziristan march...




more ▼WIKI ANALYSIS
 
TOP CONTRIBUTORS
Associate
Thomas Carey

Titan Pharmaceuticals:

Titan has a diverse and relatively advanced portfolio. Its most important drugs are licensed to others, so Titan is a somewhat passive player. The TTP pipeline includes:

1. Iloperidone - licensed to Vanda Pharmaceuticals, which has submitted an NDA to the FDA. It appears to have a strong chance of approval in 2008, it serves large market (schizophrenia), is something of a "me-too" drug.

2. Spheramine: licensed to Bayer-Schering, which is wrapping up a second phase II trial for Parkinsons disease. Anecdotal evidence suggests that it is quite effective, but it involves a brain implant, which is pretty scary. It will take a lot of time for the phase III to take place, and there are competitive treatments emerging.

3. DIPTA for hyperlipidemia: good research partner in Johns Hopkins, which is undertaking a Phase II study.

4. Probuphine: This is a delivery method for a drug to treat heroin addicts. It has many important advantages, but the patents are about to expire. This is now in a phase III trial, but it is a relatively small one and does not appear to be a pivotal trial.

5. Gallium Maltolate: Phase I not begun.




References

Retrieved from "http://www.wikinvest.com/stock/Titan_Pharmaceuticals_(TTNP)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki